Difference between revisions of "Pentostatin (Nipent)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
(Created page with "==General information== Class/mechanism: <ref name="insert">[http://products.hospira.com/assets/pdfs/EN-1503.pdf Pentostatin (Nipent) package insert]</ref><ref>[http://hemonc.org...")
 
m (Text replacement - "[http://online.lexi.com/ Lexicomp]" to "Lexicomp")
 
(29 intermediate revisions by 4 users not shown)
Line 1: Line 1:
 
==General information==
 
==General information==
−
Class/mechanism: <ref name="insert">[http://products.hospira.com/assets/pdfs/EN-1503.pdf Pentostatin (Nipent) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/pentostatin.pdf Pentostatin (Nipent) package insert (locally hosted backup)]</ref>
+
Class/mechanism: Purine (adenosine) analog, inhibitor of adenosine deaminase (ADA), causes elevated intracellular levels of dATP, and inhibits ribonucleotide reductase, which interferes with DNA synthesis.  Pentostatin can also inhibit RNA synthesis and has been observed to cause DNA damage.  ADA enzymatic activity is greater in T-cell malignancies compared to B-cell malignancies.  Exact mechanism of action in hairy cell leukemia is not fully understood.<ref name="insert">[http://labeling.pfizer.com/ShowLabeling.aspx?id=4565 Pentostatin (Nipent) package insert]</ref><ref>[[:File:Pentostatin.pdf|Pentostatin (Nipent) package insert (locally hosted backup)]]</ref><ref>[https://www.pfizerinjectables.com/products/Pentostatin Nipent manufacturer's website]</ref>
−
<br>Route: TBD
+
<br>Route: IV
−
<br>Extravasation: TBD
+
<br>Extravasation: [[neutral]]
  
−
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert<ref name="insert"></ref>.
+
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref>  
 +
 
 +
==Diseases for which it is used==
 +
*[[Chronic lymphocytic leukemia]]
 +
*[[Follicular lymphoma]]
 +
*[[Hairy cell leukemia]]
 +
*[[Marginal zone lymphoma]]
 +
*[[T-cell prolymphocytic leukemia]]
 +
*[[Waldenström macroglobulinemia]]
 +
 
 +
==Diseases for which it was used==
 +
*[[B-cell acute lymphoblastic leukemia - historical|B-cell acute lymphoblastic leukemia]]
  
 
==Patient drug information==
 
==Patient drug information==
 
*[http://chemocare.com/bio/pentostatin.asp Pentostatin (Nipent) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/pentostatin.asp Pentostatin (Nipent) patient drug information (Chemocare)]</ref>
 
*[http://chemocare.com/bio/pentostatin.asp Pentostatin (Nipent) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/pentostatin.asp Pentostatin (Nipent) patient drug information (Chemocare)]</ref>
 
*[http://www.uptodate.com/contents/pentostatin-patient-drug-information Pentostatin (Nipent) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/pentostatin-patient-drug-information Pentostatin (Nipent) patient drug information (UpToDate)]</ref>
 
*[http://www.uptodate.com/contents/pentostatin-patient-drug-information Pentostatin (Nipent) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/pentostatin-patient-drug-information Pentostatin (Nipent) patient drug information (UpToDate)]</ref>
 +
 +
==History of changes in FDA indication==
 +
* 1991-10-11: Initial approval for treatment for adult patients with alpha-interferon-refractory [[hairy cell leukemia]]. ''(Based on SWOG 8691)''
 +
 +
==Also known as==
 +
*'''Generic names:''' 2'-deoxycoformycin, dCF
 +
*'''Brand name:''' Nipent
  
 
==References==
 
==References==
 
<references/>
 
<references/>
 +
 +
[[Category:Drugs]]
 +
[[Category:Intravenous medications]]
 +
[[Category:Neutral]]
 +
 +
[[Category:Antimetabolites]]
 +
[[Category:Purine analogs]]
 +
 +
[[Category:Chronic lymphocytic leukemia medications]]
 +
[[Category:Follicular lymphoma medications]]
 +
[[Category:Hairy cell leukemia medications]]
 +
[[Category:Marginal zone lymphoma medications]]
 +
[[Category:T-cell prolymphocytic leukemia medications]]
 +
[[Category:Waldenström macroglobulinemia medications]]
 +
 +
[[Category:B-cell acute lymphoblastic leukemia medications (historic)]]
 +
 +
[[Category:FDA approved in 1991]]

Latest revision as of 12:11, 29 June 2024

General information

Class/mechanism: Purine (adenosine) analog, inhibitor of adenosine deaminase (ADA), causes elevated intracellular levels of dATP, and inhibits ribonucleotide reductase, which interferes with DNA synthesis. Pentostatin can also inhibit RNA synthesis and has been observed to cause DNA damage. ADA enzymatic activity is greater in T-cell malignancies compared to B-cell malignancies. Exact mechanism of action in hairy cell leukemia is not fully understood.[1][2][3]
Route: IV
Extravasation: neutral

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Diseases for which it was used

Patient drug information

History of changes in FDA indication

  • 1991-10-11: Initial approval for treatment for adult patients with alpha-interferon-refractory hairy cell leukemia. (Based on SWOG 8691)

Also known as

  • Generic names: 2'-deoxycoformycin, dCF
  • Brand name: Nipent

References

  1. ↑ 1.0 1.1 Pentostatin (Nipent) package insert
  2. ↑ Pentostatin (Nipent) package insert (locally hosted backup)
  3. ↑ Nipent manufacturer's website
  4. ↑ Pentostatin (Nipent) patient drug information (Chemocare)
  5. ↑ Pentostatin (Nipent) patient drug information (UpToDate)
Retrieved from "https://hemonc.org/w/index.php?title=Pentostatin_(Nipent)&oldid=87767"